Yeasts encoding tumour antigens in cancer immunotherapy

Bibliography

• RODRIGUEZ A, REGNAULT A, KLEIJMEER M, RICCIARDI-CASTAGNOLI P, AMIGORENA S: Selective transport of internalized antigens to the cytosol for MHC class I presentation in dendritic cells. Nat. Cell Biol. (1999) 1:362–368.
   PubMed Web of Science ®Google Scholar
• YEWDELL JW, NORBURY CC, BENNINK JR: Mechanisms of exogenous antigen presentation by MHC class I molecules in vitro and in vivo: implications for generating CD8+ T cell responses to infectious agents, tumors, transplants, and vaccines. Adv. ImmunoL (1999) 73:1–77.
   PubMed Web of Science ®Google Scholar
• MOORE MW, CARBONE FR, BEVAN MJ: Introduction of soluble protein into the class I pathway of antigen processing and presentation. Cell (1988) 54:777–785.
   PubMed Web of Science ®Google Scholar
• •Description of loading soluble antigen into the MHC-I pathway.
   Google Scholar
• MATZINGER P: The danger model: a renewed sense of self. Science (2002) 296:301–305.
   PubMed Web of Science ®Google Scholar
• ••Excellent review of innate immunity andthe 'danger' signals.
   Google Scholar
• MEDZHITOV R, JANEWAY CA JR: Decoding the patterns of self and nonself by the innate immune system. Science (2002) 296:298–300.
   PubMed Web of Science ®Google Scholar
• ••Excellent review of mammalian homologues of TLRs and innate immunity.
   Google Scholar
• UNDERHILL DM: Toll-like receptors: networking for success. Eur. J. ImmunoL (2003) 33:1767–1775.
   PubMed Web of Science ®Google Scholar
• AKIRA S, TAKEDA K, KAISHO T: Toll-like receptors: critical proteins linking innate and acquired immunity. Nat. ImmunoL (2001) 2:675–680.
   PubMed Web of Science ®Google Scholar
• GALLEZ-HAWKINS G, LI X, FRANCK AE et al.: DNA and low titer, helper-free, recombinant AAV prime-boost vaccination for cytomegalovirus induces an immune response to CMV-pp65 and CMV-IE1 in transgenic HLA A*0201 mice. Vaccine (2004) 23:819–826.
   PubMed Web of Science ®Google Scholar
• BASAK SK, KIERTSCHER SM, HARUI A, ROTH MD: Modifying adenoviral vectors for use as gene-based cancer vaccines. Viral ImmunoL (2004) 17:182–196.
   PubMed Web of Science ®Google Scholar
• GANTNER BN, SIMMONS RM, CANAVERA SJ, AKIRA S, UNDERHILL DM: Collaborative induction of inflammatory responses by dectin-1 and Toll-like receptor 2. J. Exp. Med. (2003) 197:1107–1117.
   PubMed Web of Science ®Google Scholar
• STUBBS AC, MARTIN KS, COESHOTT C et al.: Whole recombinant yeast vaccine activates dendritic cells and elicits protective cell-mediated immunity. Nat. Med. (2001) 7:625–629.
   PubMed Web of Science ®Google Scholar
• ••The original description of the yeastimmunotherapy platform.
   Google Scholar
• TADA H, NEMOTO E, SHIMAUCHI H et al.: Saccharomyces cerevisiae- and Candida albicans-derived mannan induced production of tumor necrosis factor alpha by human monocytes in a CD14- and Toll-like receptor 4-dependent manner. Microbiol. ImmunoL (2002) 46:503–512.
   PubMed Web of Science ®Google Scholar
• HUANG Q, LIU D, MAJEWSKI P et al.: The plasticity of dendritic cell responses to pathogens and their components. Science (2001) 294:870–875.
   PubMed Web of Science ®Google Scholar
• FALO LD JR, KOVACSOVICS-BANKOWSKI M, THOMPSON K, ROCK KL: Targeting antigen into the phagocytic pathway in vivo induces protective tumour immunity. Nat. Med. (1995) 1:649–653.
   PubMed Web of Science ®Google Scholar
• •Cross-presentation of antigens into the MHC-I pathway.
   Google Scholar
• BREINIG F, HEINTEL T, SCHUMACHER A, MEYERHANS A, SCHMITT MJ: Specific activation of CMV-primed human T lymphocytes by cytomegalovirus pp65 expressed in fission yeast. FEMS ImmunoL Med. MicrobioL (2003) 38:231–239.
   PubMed Web of Science ®Google Scholar
• HEINTEL T, BREINIG F, SCHMITT MJ, MEYERHANS A: Extensive MHC class I-restricted CD8 T lymphocyte responses against various yeast genera in humans. FEMS Immunol Med. Microbiol (2003) 39:279–286.
   PubMed Web of Science ®Google Scholar
• BUENTKE E, SCHEYNIUS A: Dendritic cells and fungi. APMIS (2003) 111:789–796.
   Web of Science ®Google Scholar
• BUENTKE E, HEFFLER LC, WALLIN RP, LOFMAN C, LJUNGGREN HG, SCHEYNIUS A: The allergenic yeast Malassezia furfur induces maturation of human dendritic cells. Clin. Exp. Allergy (2001) 31:1583–1593.
   PubMed Web of Science ®Google Scholar
• NEWMAN SL, HOLLY A: Candida albicans is phagocytosed, killed, and processed for antigen presentation by human dendritic cells. Infect. Immun. (2001) 69:6813–6822.
   PubMedGoogle Scholar
• D'OSTIANI CF, DEL SERO G, BACCI A et al.: Dendritic cells discriminate between yeasts and hyphae of the fungus Candida albicans. Implications for initiation of T helper cell immunity in vitro and in vivo. J. Exp. Med. (2000) 191:1661–1674.
   Google Scholar
• STUBBS AC, WILSON CC: Recombinant yeast as a vaccine vector for the induction of cytotoxic T-lymphocyte responses. Curr. Opin. Mol. Ther. (2002) 4:35–40.
   PubMed Web of Science ®Google Scholar
• SCHREUDER MP, DEEN C, BOERSMAWJ, POUWELS PH, KLIS FM: Yeast expressing hepatitis B virus surface antigen determinants on its surface: implications for a possible oral vaccine. Vaccine (1996) 14:383–388.
   PubMed Web of Science ®Google Scholar
• PICHUANTES S, NGUYEN A, FRANZUSOFF A: Expression of heterologous gene products in yeast. In: Protein Engineering- Principles and Practices. Cleland JL, Craik CS (Eds), Wiley-Liss, New York, NY, USA (1996):129–162.
   Google Scholar
• BOSSART P, GOLDRATH A, BUTZ E, MARTIN S, BEVAN M: Virus-mediated delivery of antigen epitopes into dendritic cells as a means to induce CTL. J. Immunol (1997) 158:3270–3276.
   PubMed Web of Science ®Google Scholar
• CHO HJ, TAKABAYASHI K, CHENG PM et al.: Immunostimulatory DNA-based vaccines induce cytotoxic lymphocyte activity by a T-helper cell-independent mechanism. Nat. Biotechnol (2000) 18:509–514.
   PubMed Web of Science ®Google Scholar
• MCCABE BJ, IRVINE KR, NISHIMURA MI et al.: Minimal determinant expressed by a recombinant vaccinia virus elicits therapeutic antitumor cytolytic T lymphocyte responses. Cancer Res. (1995) 55:1741–1747.
   PubMed Web of Science ®Google Scholar
• LU Y, BELLGRAU D, DWYER-NIELD LD et al.: Mutation-selective tumor remission with Ras-targeted, whole yeast-based immunotherapy. Cancer Res. (2004) 64:5084–5088.
   PubMed Web of Science ®Google Scholar
• ••Full description of the activity of theRas-targeted product in animals.
   Google Scholar
• BALLOU CE: A study of the immunochemistry of three yeast mannans. J. Biol. Chem. (1970) 245:1197–1203.
   PubMed Web of Science ®Google Scholar
• FRANZUSOFF A, SCHEKMAN R: Functional compartments of the yeast Golgi apparatus are defined by the sec7 mutation. EMBO J. (1989) 8:2695–2702.
   PubMed Web of Science ®Google Scholar
• BROSE MS, VOLPE P, FELDMAN M et al.: BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res. (2002) 62:6997–7000.
   PubMed Web of Science ®Google Scholar
• DOWNWARD J: Targeting RAS signalling pathways in cancer therapy. Nat. Rev. Cancer (2003) 3:11–22.
   PubMed Web of Science ®Google Scholar
• ••Excellent review of Ras in cancer.
   Google Scholar
• FOSSUM B, GEDDE-DAHL T 31d, BREIVIK J et al.: p21-ras-peptide-specific T-cell responses in a patient with colorectal cancer. CD4+ and CD8+ T cells recognize a peptide corresponding to a common mutation (13Gly- Asp). Int. J. Cancer (1994) 56:40–45.
   Google Scholar
• GEDDE-DAHL T 31d, SPURKLAND A, ERIKSEN JA, THORSBY E, GAUDERNACK G: Memory T cells of a patient with follicular thyroid carcinoma recognize peptides derived from mutated p21 ras (Gln- Leu61). Int. Immunol (1992) 4:1331–1337.
   PubMed Web of Science ®Google Scholar
• ABRAMS SI, HAND PH, TSANG KY, SCHLOM J: Mutant ras epitopes as targets for cancer vaccines. Semin. Oncol (1996) 23:118–134.
   PubMed Web of Science ®Google Scholar
• ABRAMS SI, STANZIALE SF, LUNIN SD, ZAREMBA S, SCHLOM J: Identification of overlapping epitopes in mutant ras oncogene peptides that activate CD4+ and CD8+ T cell responses. Eur. Immunol (1996) 26:435–443.
   PubMed Web of Science ®Google Scholar
• ABRAMS SI, KHLEIF SN, BERGMANN-LEITNER ES et al.: Generation of stable CD4+ and CD8+ T cell lines from patients immunized with ras oncogene-derived peptides reflecting codon 12 mutations. Cell. Immunol. (1997) 182:137–151.
   PubMed Web of Science ®Google Scholar
• GJERTSEN MK, GAUDERNACK G: Mutated Ras peptides as vaccines in immunotherapy of cancer. Vox Sang. (1998) 74\(Suppl. 2):489–495.
   Google Scholar
• GJERTSEN MK, BUANES T, ROSSELAND AR et al.: Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: clinical and immunological responses in patients with pancreatic adenocarcinoma. Int. J. Cancer (2001) 92:441–450.
   PubMed Web of Science ®Google Scholar
• HUNGER R, BRAND C, STREIT M et al.: Successful induction of immune responses against mutant ras in melanoma patients using intradermal injection of peptides and GM-CSF as adjuvant. Exp. Dermatol. (2001) 10:161–167.
   PubMed Web of Science ®Google Scholar
• KHLEIF SN, ABRAMS SI, HAMILTON JM et al.: A Phase I vaccine trial with peptides reflecting ras oncogene mutations of solid tumors. J. Immunother. (1999) 22:155–165.
   PubMed Web of Science ®Google Scholar
• CESEN-CUMMINGS K, WARNER KA, RUCH RJ: Role of protein kinase C in the deficient gap junctional intercellular communication of K-ras-transformed murine lung epithelial cells. Anticancer Res. (1998) 18:4343–4346.
   PubMed Web of Science ®Google Scholar
• LAYTON MG, FRANKS LM: Heterogeneity in a spontaneous mouse lung carcinoma: selection and characterisation of stable metastatic variants. Br. J. Cancer (1984) 49:415–421.
   PubMed Web of Science ®Google Scholar
• FORKERT PG, PARKINSON A, THAETE LG, MALKINSON AM: Resistance of murine lung tumors to xenobiotic-induced cytotoxicity. Cancer Res. (1992) 52:6797–6803.
   PubMed Web of Science ®Google Scholar
• HORIO Y, CHEN A, RICE P, ROTH JA, MALKINSON AM, SCHRUMP DS: Ki-ras and p53 mutations are early and late events, respectively, in urethane-induced pulmonary carcinogenesis in A/J mice. MoL Carcinog. (1996) 17:217–223.
   PubMed Web of Science ®Google Scholar
• NUZUM EO, MALKINSON AM, BEER DG: Specific Ki-ras codon 61 mutations may determine the development of urethan-induced mouse lung adenomas or adenocarcinomas. MoL Carcinog (1990) 3:287–295.
   PubMed Web of Science ®Google Scholar
• YANG Y, HUANG CT, HUANG X, PARDOLL DM: Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance. Nat. Immunol (2004) 5:508–515.
   PubMed Web of Science ®Google Scholar
• •Insights for overcoming tolerance in immunotherapy.
   Google Scholar